G. B. Bartley, V. Fatourechi, and E. F. Kadrmas, The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota, Am. J. Ophthalmol, vol.120, pp.511-517, 1995.

W. M. Wiersinga and L. Bartalena, Epidemiology and prevention of Graves' ophthalmopathy, Thyroid, vol.12, pp.855-860, 2002.

I. Wakelkamp, L. Baldeschi, P. Saeed, M. P. Mourits, M. F. Prummel et al., Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial, Clin Endocrinol (Oxf.), vol.63, pp.323-328, 2005.

T. Akamizu, H. Kaneko, N. Noguchi, S. Kashii, and K. Nakao, Moisture chamber for management of corneal ulcer due to Graves' ophthalmopathy, Thyroid, vol.10, pp.1123-1124, 2000.

F. Träisk and L. Tallstedt, Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction-a pilot study, Acta Ophthalmol Scand, vol.79, pp.585-588, 2001.

C. Heinz, A. Eckstein, K. Steuhl, and D. Meller, Amniotic membrane transplantation for reconstruction of corneal ulcer in graves ophthalmopathy, Cornea, vol.23, pp.524-526, 2004.

J. D. Trobe, J. S. Glaser, and P. Laflamme, Dysthyroid optic neuropathy. Clinical profile and rationale for management, Arch Ophthalmol, vol.96, pp.1199-1209, 1978.

C. Jeon, J. H. Shin, K. I. Woo, and Y. Kim, Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy, Korean J Ophthalmol, vol.26, pp.73-79, 2012.

P. Mourits, M. Kalmann, R. Sasim, and I. V. , Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy, Orbit Amst Neth, vol.20, pp.275-280, 2001.

D. Mckeag, C. Lane, and J. H. Lazarus, Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey, Br J Ophthalmol, vol.91, pp.455-458, 2007.

P. Perros, M. ?arkovi?, and C. Azzolini, PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from, Br J Ophthalmol, vol.99, pp.1531-1535, 2000.

A. J. Dickinson, Graves' Orbitopathy: A Multidisciplinary Approach, pp.1-27, 2007.

N. Currò, D. Covelli, and G. Vannucchi, Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy, Thyroid, vol.24, pp.897-905, 2014.

I. Pascual-camps, R. Molina-pallete, M. A. Bort-martí, J. Todolí, and E. España-gregori, Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy, Orbit Amst Neth, vol.8, pp.1-4, 2018.

L. Bartalena, L. Baldeschi, and K. Boboridis, European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy, Eur. Thyroid J, vol.5, pp.9-26, 2016.

J. R. Guy, S. Fagien, J. P. Donovan, and M. L. Rubin, Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy, Ophthalmology, vol.96, pp.1048-1053, 1989.

H. Stiebel-kalish, E. Robenshtok, M. Hasanreisoglu, D. Ezrachi, I. Shimon et al., Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis, J Clin Endocrinol Metab, vol.94, pp.2708-2716, 2009.

S. Zang, K. A. Ponto, and G. J. Kahaly, Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity, J Clin Endocrinol Metab, vol.96, pp.320-332, 2011.

E. Sisti, B. Coco, and F. Menconi, Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study, Eur J Endocrinol, vol.172, pp.269-276, 2015.

P. Mi?kiewicz, B. Rutkowska, and A. Jab?o?ska, Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy, Endokrynol Pol, vol.67, pp.166-173, 2016.